3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.

  • Authors:
    • N K Cheung
    • B H Kushner
    • S D Yeh
    • S M Larson
  • View Affiliations

  • Published online on: June 1, 1998     https://doi.org/10.3892/ijo.12.6.1299
  • Pages: 1299-1605
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside GD2. In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had stage 4 neuroblastoma. Response was seen in bony lesions (2 of 7 pts) and marrow (3 of 8 pts). Acute toxicities of pain, fever, urticaria, hypertension, hypotension and anaphylactoid reactions were self-limited and manageable. Three pts are long-term survivors between 79-130+ months after 3F8 treatment without additional systemic therapy and no delayed neurological complications. The potential benefits of 3F8 when added to chemoradio-therapy warrant further investigation.

Related Articles

Journal Cover

Jun 1998
Volume 12 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cheung N, Kushner B, Yeh S and Larson S: 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.. Int J Oncol 12: 1299-1605, 1998
APA
Cheung, N., Kushner, B., Yeh, S., & Larson, S. (1998). 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.. International Journal of Oncology, 12, 1299-1605. https://doi.org/10.3892/ijo.12.6.1299
MLA
Cheung, N., Kushner, B., Yeh, S., Larson, S."3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.". International Journal of Oncology 12.6 (1998): 1299-1605.
Chicago
Cheung, N., Kushner, B., Yeh, S., Larson, S."3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.". International Journal of Oncology 12, no. 6 (1998): 1299-1605. https://doi.org/10.3892/ijo.12.6.1299